Pharmaceutical composition for preventing or treating alzheimer's and use thereof

A method of treating Alzheimer's disease, the method comprising:

• administering a pharmaceutical composition comprising a manipulated stem cell as an active ingredient into a subject,
• wherein the manipulated stem cell comprises an engineered gene having an indel in a wild-type HIF1AN gene,
• a sequence of the engineered HIF1AN gene is different from the original sequence of the wild-type HIF1AN gene,
• FIH-1 exhibits a lower expression level in the manipulated stem cell than in the wild-type cell, and
• HIFα exhibits a higher expression level in the manipulated stem cell than in the wild-type cell.

A method of treating Alzheimer's disease, the method comprising:

• administering a pharmaceutical composition comprising a manipulated stem cell as an active ingredient into a subject,
• wherein the manipulated stem cell comprises an engineered HIF1AN gene,
• the engineered HIF1AN gene does not comprise one or more sequences selected from SEQ ID NOs:1 to 9,
• FIH-1 exhibits a lower expression level in the manipulated stem cell than in the wild-type cell, and
• HIFα exhibits a higher expression level in the manipulated stem cell than in the wild-type cell.

A use of a manipulated stem cell for treating Alzheimer's disease,

• wherein the use comprises administering a pharmaceutical composition comprising a manipulated stem cell as an active ingredient into a subject,
• the manipulated stem cell comprises an engineered gene having an indel in a wild-type HIF1AN gene,
• a sequence of the engineered HIF1AN gene is different from the original sequence of the wild-type HIF1AN gene,
• FIH-1 exhibits a lower expression level in the manipulated stem cell than in the wild-type cell, and
• HIFα exhibits a higher expression level in the manipulated stem cell than in the wild-type cell.

A use of a manipulated stem cell for treating Alzheimer's disease,

• wherein the use comprises administering a pharmaceutical composition comprising a manipulated stem cell as an active ingredient into a subject,
• the manipulated stem cell comprises an engineered HIF1AN gene,
• the engineered HIF1AN gene does not comprise one or more sequences selected from SEQ ID NOs:1 to 9,
• FIH-1 exhibits a lower expression level in the manipulated stem cell than in the wild-type cell, and
• HIFα exhibits a higher expression level in the manipulated stem cell than in the wild-type cell.

A use of a manipulated stem cell for the manufacture of a medicament for treatment of Alzheimer's disease,

• wherein the manipulated stem cell comprises:
• an engineered gene having an indel in a wild-type HIF1AN gene,
• wherein a sequence of the engineered HIF1AN gene is different from the original sequence of the wild-type HIF1AN gene,
• FIH-1 exhibits a lower expression level in the manipulated stem cell than in the wild-type cell, and
• HIFα exhibits a higher expression level in the manipulated stem cell than in the wild-type cell.

A use of a manipulated stem cell for the manufacture of a medicament for treatment of Alzheimer's disease,

• wherein the use comprises administering a pharmaceutical composition comprising a manipulated stem cell as an active ingredient into a subject,
• wherein the manipulated stem cell comprises an engineered HIF1AN gene,
• the engineered HIF1AN gene does not comprise one or more sequences selected from SEQ ID NOs:1 to 9,
• FIH-1 exhibits a lower expression level in the manipulated stem cell than in the wild-type cell, and
• HIFα exhibits a higher expression level in the manipulated stem cell than in the wild-type cell.